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1078–5Purpose. To evaluate the maturation and patency of transposed brachio-basilic fistulae that had been chosen based on the
results of preoperative imaging techniques.
Methods. Among 215 patients admitted to our clinic requiring arteriovenous fistulae between May 2004 and September
2005, 59 were scheduled for a transposed brachio-basilic fistula procedure. The relationship between demographic data, lab-
oratory values, invasive and noninvasive imaging studies with patency and maturation time of the fistulae were evaluated
by univariate analyses.
Results. Primary and secondary patency rates were 82% and 97% at 6 months 72% and 92% at one year respectively. The
only parameter found to affect maturation time was basilic vein diameter. The maturation time was 59.3 22.3 days
(range 32e92 days) for veins less than 3 mm in diameter and 24.7 4.4 days (range, 21 to 34 days) for those with larger
diameters. The number of previously failed fistulae correlated with a decrease in primary patency time. The primary pa-
tency rate at 1 year was 58.9% for patients whose preoperative arterial flow rate was below 70 cm/sec, while it was
93.3% when the flow was greater.
Conclusion. We believe that this type of fistula should be the first option in patients in whom the cephalic vein is inap-
propriate for a vascular access. Preoperative evaluation of the arterial system as well as a history of previous access failure
may be considered predictive parameters for the patency of the fistulae.
 2007 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.
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The number of patients requiring regular hemodialy-
sis therapy is approximately 300 000 in the United
States and exceeds 25 000 in Turkey (according to
the Turkish Nephrology Society in 2004). Treatment
for these patients takes a significant proportion of
the nation’s financial healthcare reserves and has an
influence on the national economy.1,2 According to
the principles of The National Kidney Foundation
Dialysis Outcomes Quality (NKF/DOQ) guidelines
it is suggested that at least half of these patients be
connected to the machines through established arte-
riovenous fistulae (AVF).3 In 2002 a prospective studysponding author. M. Haberal, MD, FACS, FICS (Hon),
l Surgery and Transplantation, Baskent Universitesi Rektor-
Cad. No:77 Kat:4 Bahcelievler, 06490, Ankara, Turkey.
address: rektorluk@baskent-ank.edu.tr
884/000208+ 06 $34.00/0  2007 Published by Elsevier Ltd on(The Dialysis Outcomes and Practice Patterns Study)
was conducted using data from 309 dialysis centers
in the United States, which found that an AVF was
used as an access port in only 24% of hemodialysis
patients, whereas this figure in Europe was 80%.4 A
similar assessment of 25 321 patients in Turkey found
that 90% of patients having haemodialysis had AVF.2
Although the rate of creating AVF in our country is
better than our target minimum, the decision regard-
ing which site to use for access remains problematic.
In patients in whom the cephalic vein is thrombosed
or has been used for previous access, the alternatives
include brachio-basilic or brachio-axillary AV grafts
using synthetic materials or a transposed brachio-
basilic fistula. The advantages of using AVF compared
with prosthetic grafts include increased patency and
decreased infection rates.5e9
The objective of this prospective clinical study was
to evaluate the maturation and patency periods ofbehalf of European Society for Vascular Surgery.
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209Imaging Findings and Fistula for Hemodialysistransposed brachio-basilic fistulae that were chosen
based on the results of preoperative imaging tech-
niques and also, to evaluate the effect of possible pa-
rameters that might play a role in maturation and
patency results.Fig. 1. A brachio-basilic transposition fistula, created using 3
transverse incisions over the medial aspect of the upper arm
in a patient with failed cephalic antecubital fistula. 1a: Tu-
nneled basilic vein. 1b: Brachiobasilic anastomosis.Materials and Methods
Between May 2004 and September 2005 preoperative
venography was performed on 215 consecutive pa-
tients who required vascular access for hemodialysis.
The choice of which extremity to use for access was
based on the results of physical examinations and pre-
vious central catheterization or AVF sites. Among
these 215 patients, transposed brachio-basilic fistulas
were created in 59 patients.
During preoperative venograms, the superficial
vein in the hand or forearm was cannulated, and ve-
nous runoff from the superficial veins to the superior
vena cava was imaged using digital subtraction angi-
ography (Multistar TOP Siemens, Germany). Patients
whose venograms demonstrated that their central
veins were patent but whose cephalic veins were not
appropriate above the level of the antecubital fossa
were considered for a transposed brachio-basilic
AVF and were included in this study. During the pre-
operative period, the arterial pulses of the extremity
were evaluated using the Allen test. Blood pressure
measurements were taken for both upper extremities,
and pressure gradient differences were investigated.
Patencyand flow rate of the brachial artery at the level
of the antecubital fossa was investigated by Doppler
ultrasonography (US). In patients with symptomatic
or significant arterial stenosis and with pressure
gradient differences greater than 15 mm Hg, the
brachial artery was not accepted as an appropriate
inflow artery. The diameter of the basilic vein also
was measured during this procedure, with 2 mm
being considered the minimum appropriate vein
diameter.
All surgical procedures were performed under lo-
cal anesthesia. Three transverse incisions were made
over the medial aspect of the upper arm (Fig. 1).
The basilic vein was identified under all these inci-
sions and exposed from the antecubital fossa toward
the axillary vein. All side branches of the basilic
vein were ligated. The brachial artery was identified
and mobilized above the antecubital fossa through
the lower transverse incision. After a subcutaneous
tunnel had been created on the lateral side of the
arm, the basilic vein was ligated and divided distally.
The anastomosis between the basilic vein and the
brachial artery was created using 7-0 polypropylenesuture material in an end-to-side fashion. All patients
received a single 1-g IV dose of ampicillin-sulbactam
for prophylaxis and were heparinized during the
operation, just after arterial clamp placement.
The patency and flow rate of the fistula were eval-
uated and recorded by Doppler US on the first day
after surgery. Patients were followed regularly until
the fistula could be used as a vascular access for he-
modialysis. Fistulae were used for hemodialysis no
sooner than the 21 days after the procedure, and the
choice to use them was based on the results of a phys-
ical examination, existence of thrill, and radiologic
findings when necessary. AVF that could be used for
6 consecutive hemodialysis sessions were accepted
as being of sufficient maturation. Until that point, he-
modialysis was performed through central catheters.
Thromboses detected on follow-up were treated
with percutaneous procedures. Thromboses were sus-
pected based on loss of the thrill at the AVF site, and
each diagnosis was confirmed with Doppler US. If the
thrill was restored during the intervention and control
Doppler US examination indicated sufficient flow, the
procedure was considered successful. In the case of
AVF thrombosis mechanical balloon thrombectomy
was performed, and 2000e3000 IU heparin was
administered during this procedure. In addition,
pulse-spray streptokinase treatment (total dose 150
000e350 000 IU) was administered. After percutane-
ous thrombectomy, patency of the fistula was evalu-
ated with a fistulogram. Additionally, in each case
where there was a stenotic segment, percutaneous
transluminal angioplasty was performed with a 5- to
8-mm diameter balloon catheter.
The influence of the age of the patients, prior num-
ber of fistulae, ESRD aetiologies, hemoglobin and
platelet levels, preoperatively evaluated brachialEur J Vasc Endovasc Surg Vol 35, February 2008
Table 1. Demographic data, preoperative/postoperative imaging
findings and laboratory values
Number of patients 51
Age 55.39 12.79 (35e88)
Sex F/M 17/34
Hemoglobin (g/dL) 9.80 1.49 (7.2e13)
Diabetes 45% (n¼ 15)
Platelet (1000/mL) 211.000 103.271 (67e549000)
Albumin (g/dL) 3.4 0.5 (4.9e2.2)
Artery diameter (mm) 4.7 1.09 (3e7)
Vein diameter (mm) 4.06 1.24 (2e6)
Fistula flow (at 1 day) cm/sec 272.24 94.447 (126e582)
Artery flow (cm/sec) 63.36 19.27 (25e95)
Number of previous fistulas 2.58 2.13 (0e7)
Maturation duration (day) 34.47 19.79 (21e92)
210 F. Y. Karakayali et al.artery flow rates, preoperative measures of basilic and
brachial artery diameters, AVF flow rates 24 hours af-
ter surgery, and patency and maturation of the fistulae
were evaluated by univariate and multivariate
analyses.
All final evaluations were completed at the end of
the first year after surgery. Primary patency of the
transposed brachial-basilic fistulae was defined as
the period between creating the AVF and the first
required radiologic or surgical intervention, or the
time of final patency assessment. Secondary patency
time was defined as the period between creating the
AVF and an irreversible thrombosis of the fistula or
the time of measurement of patency including all
interventions.Statistical analyses
Statistical analyses were performed using SSPS
software (Statistical Package for the Social Sciences,
version 11.0, SSPS Inc, Chicago, IL, USA). Results
were expressed as mean values SD and percentage,
with P< .05 considered significant. The Pearson
product moment correlation analysis was used to
determine parameters affecting maturation duration.
The correlation between vein size and maturation du-
ration was evaluated with the Mann-Whitney U test.
Cox univariate and multivariate regression analyses
were performed to analyze factors affecting patency.
Patency curves were generated by the Kaplan-Meier
method.Table 2. Statistical impact of the parameters that may influence
maturation time of the vascular access
P R
Age .137 0.269
Diabetes .511 0.118
Number of previous fistula history .513 0.120
Hemoglobin (g/dL) .654 0.082
Platelet (1000/mL) .870 0.030
Artery flow cm/sec .508 0.121
Vein diameter (mm) .0001* 0.745*
Fistula flow cm/sec (at 1 day) .471 0.132
Artery diameter (mm) .513 0.295
*P value significant.
R: correlation coefficient.Results
According to preoperative physical examinations as
well as invasive and noninvasive imaging findings,
59 patients were found to be appropriate candidates
for transposed brachial-basilic fistulas. 8 of these
patients were lost to follow-up. The remaining 51
patients (17 women, 34 men; mean age, 55.3 12.5
years) composed our study population. The cause of
ESRD was diabetes in 23 patients (45%). All patients
were undergoing dialysis treatment at the time of
the access procedure. The number of previous access
sites ranged between 0 and 7 (Table 1).
Mean maturation time or the mean time of the first
puncture and use of the fistula was 34.47 19.79 days
(range, 21e92 days). Successful maturation of the AVF
was achieved in 50 patients with a 98% success rate.
The only parameter found to affect maturation time
was basilic vein diameter (Table 2). For veins less
than 3 mm in diameter, the maturation time was
59.3 22.3 days (range, 32e92 days), while it wasEur J Vasc Endovasc Surg Vol 35, February 200824.7 4.4 days (range, 21 to 34 days) for those larger
than 3 mm in diameter (P<.0001) (Fig. 2).
Six early postoperative complications (11.7%) were
identified; there were 4 postoperative hematomas and
2 lymphatic leakages but none required an operation.
Late ischemic steal syndrome occurred in 1 patient 16
months after surgery.
During follow-up, 14 patients (28%) required inter-
ventions for thromboses, 2 also had segmental steno-
ses in the outflow vein, and 3 had stenoses in the
ipsilateral central vein. All except 3 could be rescued
with percutaneous interventional procedures. The ac-
cess failure rate on follow-up was 6%. At final assess-
ment, 47 of the AVF (92%) were still patent.
Considering only AVF that had matured, primary
and secondary patency rates at 6 months were 82%
and 97%. Primary and secondary patency rates at 1
year were 72% and 92% (Fig. 3). We found the number
of previously failed fistulae correlated with a decrease
in primary patency time (P< .005). The mean number
of previously failed fistulas was 5.38 1.88 (median,
5) for patients who required revision during follow-
up, while it was 1.52 1.2 (median, 1) for those with
no problem (P< .0001). There also was a direct corre-
lation between preoperative brachial artery flow and 1
year primary patency rate of the fistulas (P< .005)
vein diameter >=3 mm
vein diameter <3 mm
M
at
ur
at
io
n 
D
ur
at
io
n
100
80
60
40
20
0
Fig. 2. Comparison between vein diameter and maturation
time (Mann-Whitney U test).
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was 58.9% for patients whose preoperative arterial
flow rate was below 70 cm/sec, while it was 93.3%
when the flow was greater (Fig. 4).Time (months)
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Fig. 3. Kaplan-Meier primary and secondary patency curves
of all fistulas.Discussion
Studies have reported that both invasive and noninva-
sive preoperative vascular imaging (PVI), prior to es-
tablishing AVF for hemodialysis are useful.10e15
However, most of those studies were retrospectively
designed to evaluate the effect of the PVI studies on
various fistula types. In this prospective study, the in-
fluence of PVI on the outcome of brachio-basilic AVF
alone was investigated.
When brachiocephalic fistulae fail or no cephalic
vein can be found above the antecubital level, we pre-
viously performed either brachiobasilic or brachioax-
illary AV grafts. With increasing experience and the
ability to evaluate the basilic vein via PVI methods,
we began to perform basilic vein transposition in
every patient in whom the cephalic vein could not be
visualized above the antecubital fossa. Another point
of debate is whether application of a forearm pros-
thetic graft is an option following establishment of an-
tecubital grafts in cases when there is no patent
cephalic vein.14 Previously, in patients with failed fore-
arm brachio-basilic AVGs, we found that the basilic
vein was sometimes ineligible for a transposition
fistula. It has been documented that brachial AVgrafts
have secondary patency rates of 62% to 70% at 1 year.7
In our study the secondary patency rate for basilic vein
transposition at 1 year was 92%, an outcome better
than reported in most investigations.16e20 This most
likely is the result of PVI studies, close postoperative
follow-up, and early diagnosis of complications such
as thromboses and immediate interventions.
We use arterial Doppler US and venography as PVI
studies. As our hospital is a reference center in the re-
gion, most patients are on long-term hemodialysis
treatment with serious access problems, so we need
to determine the patency of the central veins. Thus
in our practice, the venous anatomy was evaluated
by venography. After deciding on the appropriate
outflow vein (depending on the venographyTable 3. Statistical impact of the parameters that may influence the
primary patency of the vascular access by Cox univariate analysis
P OR CI
Age .368 0.970 0.9091.036
Diabetes .456 1.829 0.3748.937
Number of previous fistula history .005* 3.781 1.4969.554
Hemoglobin (g/dL) .323 0.738 0.4041.348
Platelet (1000/mL) .290 1 1.01.0
Artery flow cm/sec .005* 0.907 0.8470.971
Vein diameter (mm) .683 1.417 0.2677.521
Maturation duration .487 0.983 0.9381.031
Fistula flow cm/sec (at 1 day) .063 0.989 0.9781.001
Artery diameter .826 0.924 0.4561.872
*P values significant.
OR: odds ratio, CI: confidence interval.
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Table 4. Statistical impact of the parameters that may influence the
primary patency of the vascular access by Cox multivariate
analysis
P OR CI
Age .071 1.202 0.984e1.468
Diabetes .129 8.944 0.528e15.575
Number of previous fistula history .013* 7.074 1.514e33.060
Vein diameter (mm) .068 9.534 0.467e61.958
Fistula flow cm/sec (at 1 day) .466 1.005 0.991e1.020
Artery flow cm/sec .015* 0.828 0.710e0.965
Artery diameter .656 0.649 0.710e0.965
*P values significant.
OR: odds ratio, CI: confidence interval.
212 F. Y. Karakayali et al.findings), the inflow artery was determined by Dopp-
ler US. If no inflow artery were available, then the pa-
tient was re-evaluated for a different access site. As
mentioned earlier, in 95% of patients, the basilic vein
is of adequate quality and caliber for access creation.21
In the present study, in cases in which both the central
and basilic veins were patent, we were able to create
a brachio-basilic transposition AVF in all patients. It
is beyond doubt that the diameter of the vein deter-
mined with PVI has an impact on maturation of the
fistula. Basilic veins with good calibration and diame-
ters larger than 2 mm were accepted as appropriate
outflow veins in our study. Although 2 mm might
be considered small for such a fistula procedure, other
alternatives are of uncertain value, such brachio-axil-
lary AV graft or transposition of the brachial vein.
2 mm was the minimum basilic vein diameter mea-
sured in our study, so none of the patients had to bePrimary Patency
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Fig. 4. Influence of arterial flow rate on primary patency of
the fistula.
Eur J Vasc Endovasc Surg Vol 35, February 2008excluded because the basilic vein was too narrow.
Successful maturation occurred in 98% of the AVF,
compared with rates of 62%e95% reported in the lit-
erature.8,16,19,20,22e24 As there was only 1 immature fis-
tula in our series, it is not possible to compare and
comment on the parameters influencing maturation.
However, we believe that the most important factor
is to choose the most appropriate vascular structures
by PVI. According to our data, the only parameter
that affects maturation time is vein diameter. AVF us-
ing basilic veins with diameters larger than 3 mm
could be used for hemodialysis in the short term.
Although in our study, we found that arterial flow
rates greater than 70 cm/sec significantly prolonged
the primary patency on Kaplan-Meier analysis, fur-
ther studies are needed to estimate the normal arterial
blood flow rate in healthy individuals of similar age
groups. We believe that factors other than age (eg,
duration of ESRD, additional medical problems, and
preoperative arterial flow findings) are more impor-
tant in predicting patency outcomes.
In a previous article a primary patency rate of 23%
at 1 year was reported. All failures were due to steno-
ses in the outflow or central veins.20 Significant func-
tional stenoses are associated with a high rate of
fistula thrombosis.25 In our series, the revision rate
was 28% and 35.7% of these patients had accompany-
ing stenoses. We believe these stenoses were related to
repeated cannulation.
In our series, in patients with a history of access
failure, the risk of thrombosis was increased 3 to 7
fold. However, we were able to rescue 78.5% of these
thrombosed fistulae with interventional procedures.
Gibso and coworkers18 compared basilic transposition
fistulae patients with a history of failed access with
autogenous brachio-cephalic fistulae and upper-arm
AV grafts, and reported equivalent patency rates.
However, the rate of reinterventions was lower in
the basilic transposition group. The authors claim
that basilic vein transposition represents the ideal ac-
cess conduit in patients in whom simple AVFs or
prosthetic grafts have failed, as patients with previ-
ously failed access sites may already have used their
forearm veins or had poor forearm veins to begin
with. Previous proximal cannulizations of the superfi-
cial cephalic vein for hemodialysis may cause stenoses
at needle insertion sites, which subsequently may re-
sult in thromboses of the outflow vein. Such problems
are unlikely with the basilica vein due to its deeper
subfascial localization.
In our patients, the mean number of previously
failed access sites was 5 for patients who had expe-
rienced a thrombosis during follow-up, while it
was 1.5 for patients who did not experience
213Imaging Findings and Fistula for Hemodialysisa thrombosis during follow-up. This finding sug-
gests hypercoagulability as a reason for repeated
thromboses or that fistula failure also may be related
to a tendency for venous hyperplasia. As there were
no patients with a known hypercoagulable state in
our group, we used aspirin (100 mg) for thrombosis
prophylaxis. We suggest that in patients with a his-
tory of frequent access thromboses that a detailed
hematologic evaluation should be obtained. This ap-
proach may allow for appropriate antithrombotic
prophylactic treatment, which will increase the pri-
mary patency of the created vascular access. In
fact, the process of thrombosis development is mul-
tifactorial. Venous stenoses and the inappropriate
catheterization techniques during dialysis are the
main precipitating factors. Selection of the correct
vascular access site and type by PVI, close postoper-
ative monitoring of access flow and venous dialysis
pressure and continuing education about dialysis
for nurses and health care staff are the crucial factors
that may improve vascular access survival.
The brachio-basilic transposition AVF created after
PVI studies have high maturation and patency rates
and low morbidity rates. We believe that this type of
fistula should be the first option, in patients in
whom the cephalic vein is inappropriate for a vascular
access. The higher primary patency rates in patients
with preoperative arterial flow rates of at least
70 cm/second suggest that preoperative invasive
and noninvasive evaluation of the arterial system
may predict patency of the fistula. We observed de-
creased primary patency rates in patients with high
rates of previous thromboses or failed fistulae.References
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